Abatacept in the treatment of lupus

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

In contrast to other areas in rheumatology, the therapeutic armamentarium in systemic lupus erythematosus (SLE) has lagged behind due to a number of reasons. While SLE is the prototypical multi-system autoimmune disease, its low incidence and the heterogeneity in its clinical manifestations have made it difficult to study. Despite advances in the understanding and application of immunology, the emergence of new targets has not been successfully validated largely due to the difficult-to-use outcome measures. Among the many targets studied, co-stimulation blockade that prevents activation of T cells by antigen-presenting cells, poses an interesting concept that is plausible based on basic science, animal and early human studies. AREAS COVERED: The authors hereby review the development of abatacept in the treatment of SLE and possible future directions. EXPERT OPINION: Despite failure to achieve primary efficacy end points, the studies of abatacept in lupus provided tantalising evidence that co-stimulatory blockade is a feasible option worthy of further exploration.
Original languageEnglish
Pages (from-to)1399 - 1406
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume12
Issue number10
DOIs
Publication statusPublished - 2012

Cite this

@article{6e68857f0b0f4334a48861ada3dd4e18,
title = "Abatacept in the treatment of lupus",
abstract = "In contrast to other areas in rheumatology, the therapeutic armamentarium in systemic lupus erythematosus (SLE) has lagged behind due to a number of reasons. While SLE is the prototypical multi-system autoimmune disease, its low incidence and the heterogeneity in its clinical manifestations have made it difficult to study. Despite advances in the understanding and application of immunology, the emergence of new targets has not been successfully validated largely due to the difficult-to-use outcome measures. Among the many targets studied, co-stimulation blockade that prevents activation of T cells by antigen-presenting cells, poses an interesting concept that is plausible based on basic science, animal and early human studies. AREAS COVERED: The authors hereby review the development of abatacept in the treatment of SLE and possible future directions. EXPERT OPINION: Despite failure to achieve primary efficacy end points, the studies of abatacept in lupus provided tantalising evidence that co-stimulatory blockade is a feasible option worthy of further exploration.",
author = "Alberta Hoi and Littlejohn, {Geoffrey Owen}",
year = "2012",
doi = "10.1517/14712598.2012.713934",
language = "English",
volume = "12",
pages = "1399 -- 1406",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor & Francis",
number = "10",

}

Abatacept in the treatment of lupus. / Hoi, Alberta; Littlejohn, Geoffrey Owen.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 10, 2012, p. 1399 - 1406.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Abatacept in the treatment of lupus

AU - Hoi, Alberta

AU - Littlejohn, Geoffrey Owen

PY - 2012

Y1 - 2012

N2 - In contrast to other areas in rheumatology, the therapeutic armamentarium in systemic lupus erythematosus (SLE) has lagged behind due to a number of reasons. While SLE is the prototypical multi-system autoimmune disease, its low incidence and the heterogeneity in its clinical manifestations have made it difficult to study. Despite advances in the understanding and application of immunology, the emergence of new targets has not been successfully validated largely due to the difficult-to-use outcome measures. Among the many targets studied, co-stimulation blockade that prevents activation of T cells by antigen-presenting cells, poses an interesting concept that is plausible based on basic science, animal and early human studies. AREAS COVERED: The authors hereby review the development of abatacept in the treatment of SLE and possible future directions. EXPERT OPINION: Despite failure to achieve primary efficacy end points, the studies of abatacept in lupus provided tantalising evidence that co-stimulatory blockade is a feasible option worthy of further exploration.

AB - In contrast to other areas in rheumatology, the therapeutic armamentarium in systemic lupus erythematosus (SLE) has lagged behind due to a number of reasons. While SLE is the prototypical multi-system autoimmune disease, its low incidence and the heterogeneity in its clinical manifestations have made it difficult to study. Despite advances in the understanding and application of immunology, the emergence of new targets has not been successfully validated largely due to the difficult-to-use outcome measures. Among the many targets studied, co-stimulation blockade that prevents activation of T cells by antigen-presenting cells, poses an interesting concept that is plausible based on basic science, animal and early human studies. AREAS COVERED: The authors hereby review the development of abatacept in the treatment of SLE and possible future directions. EXPERT OPINION: Despite failure to achieve primary efficacy end points, the studies of abatacept in lupus provided tantalising evidence that co-stimulatory blockade is a feasible option worthy of further exploration.

UR - http://informahealthcare.com/doi/pdf/10.1517/14712598.2012.713934

U2 - 10.1517/14712598.2012.713934

DO - 10.1517/14712598.2012.713934

M3 - Article

VL - 12

SP - 1399

EP - 1406

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -